| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
63,780,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.000001 - $1.16 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile RVL Pharmaceuticals is a holding company. Through its subsidiaries, Co. is a pharmaceutical company focused on the commercialization and development of products that target markets with underserved patients in the ocular medicine and medical aesthetics therapeutic areas. Co.'s portfolio includes RVL-1201, or Upneeq, (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or droopy or low-lying eyelids in adults. Co. has expanded its commercialization activities among ophthalmology, optometry and oculoplastic specialties. Co. makes Upneeq available through RVL Pharmacy, Inc., its wholly-owned pharmacy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
25,000,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$38,750,000 |
| Total People Bought |
0 |
0 |
0 |
5 |
| Total Buy Transactions |
0 |
0 |
0 |
5 |
| Total Shares Sold |
0 |
35,088,392 |
35,088,392 |
35,088,392 |
| Total Sell Value |
$0 |
$1,602,356 |
$1,602,356 |
$1,602,356 |
| Total People Sold |
0 |
2 |
2 |
2 |
| Total Sell Transactions |
0 |
6 |
6 |
6 |
| End Date |
2024-01-18 |
2023-10-17 |
2023-04-18 |
2022-04-18 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Lask Alisa |
Director |
– • – |
2022-08-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
9,557 |
|
-34% |
|
| Lask Alisa |
Director |
– • – |
2022-08-10 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
84,557 |
|
- |
|
| Ferrell Jeffrey |
10% Owner |
– – • |
2022-08-08 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
14,600,444 |
|
-28% |
|
| Burgstahler David F |
Director |
– • • |
2022-08-08 |
4 |
B |
$1.55 |
$12,400,000 |
I/I |
8,000,000 |
23,730,864 |
2.25 |
-28% |
|
| Markison Brian A |
Chief Executive Officer |
• • – |
2022-08-08 |
4 |
B |
$1.55 |
$1,317,500 |
D/D |
850,000 |
2,976,020 |
2.81 |
-28% |
|
| Schaub James |
EVP and COO |
• – – |
2022-08-08 |
4 |
B |
$1.55 |
$232,500 |
D/D |
150,000 |
540,020 |
2.74 |
-28% |
|
| Orbit Co-Invest Iii Llc |
10% Owner |
– – • |
2022-08-08 |
4 |
B |
$1.55 |
$12,400,000 |
D/D |
8,000,000 |
23,730,864 |
2.45 |
-28% |
|
| Venkataraman Sriram |
Director |
– • • |
2022-08-08 |
4 |
B |
$1.55 |
$12,400,000 |
I/I |
8,000,000 |
23,730,864 |
2.25 |
-28% |
|
| Devries Tina Marie |
EVP, Research & Development |
• – – |
2022-05-18 |
4 |
D |
$1.40 |
$7,626 |
D/D |
(5,447) |
136,141 |
|
- |
|
| Klein Christopher |
General Counsel & Secretary |
• – – |
2022-05-18 |
4 |
D |
$1.40 |
$8,578 |
D/D |
(6,127) |
195,628 |
|
- |
|
| Schaub James |
EVP and COO |
• – – |
2022-05-18 |
4 |
D |
$1.40 |
$8,782 |
D/D |
(6,273) |
390,020 |
|
- |
|
| Schaub James |
EVP and COO |
• – – |
2022-01-24 |
4 |
D |
$1.13 |
$10,856 |
D/D |
(9,607) |
396,293 |
|
- |
|
| Einhorn Andrew J. |
Chief Financial Officer |
• – – |
2022-01-24 |
4 |
D |
$1.13 |
$10,856 |
D/D |
(9,607) |
141,473 |
|
- |
|
| Klein Christopher |
General Counsel & Secretary |
• – – |
2022-01-24 |
4 |
D |
$1.13 |
$10,856 |
D/D |
(9,607) |
201,755 |
|
- |
|
| Devries Tina Marie |
EVP, Research & Development |
• – – |
2022-01-24 |
4 |
D |
$1.13 |
$10,856 |
D/D |
(9,607) |
141,588 |
|
- |
|
| Schaub James |
EVP and COO |
• – – |
2021-12-16 |
4 |
B |
$1.07 |
$100,366 |
D/D |
93,800 |
405,900 |
2.74 |
32% |
|
| Cowan Gregory L |
Director |
– • – |
2021-08-27 |
4 |
D |
$3.31 |
$18,225 |
D/D |
(5,506) |
50,055 |
|
- |
|
| Weiss Fred G |
Director |
– • – |
2021-08-27 |
4 |
D |
$3.31 |
$18,225 |
D/D |
(5,506) |
118,466 |
|
- |
|
| Weiss Fred G |
Director |
– • – |
2021-07-02 |
4 |
A |
$0.00 |
$0 |
D/D |
61,188 |
123,972 |
|
- |
|
| Weiss Fred G |
Director |
– • – |
2021-06-18 |
4 |
D |
$2.89 |
$53,708 |
D/D |
(18,584) |
62,784 |
|
- |
|
| Cowan Gregory L |
Director |
– • – |
2021-06-18 |
4 |
D |
$2.89 |
$53,708 |
D/D |
(18,584) |
55,561 |
|
- |
|
| Einhorn Andrew J. |
Chief Financial Officer |
• – – |
2021-05-18 |
4 |
D |
$3.12 |
$20,177 |
D/D |
(6,467) |
151,080 |
|
- |
|
| Klein Christopher |
General Counsel & Secretary |
• – – |
2021-05-18 |
4 |
D |
$3.12 |
$20,177 |
D/D |
(6,467) |
211,362 |
|
- |
|
| Schaub James |
EVP and COO |
• – – |
2021-05-18 |
4 |
D |
$3.12 |
$20,658 |
D/D |
(6,621) |
312,100 |
|
- |
|
| Devries Tina Marie |
EVP, Research & Development |
• – – |
2021-05-18 |
4 |
D |
$3.12 |
$20,177 |
D/D |
(6,467) |
151,195 |
|
- |
|
34 Records found
|
|
Page 1 of 2 |
|
|
